List of Contents

Anti-Biofilm Wound Dressing Industry will Escalate Rapidly in the Near Future

In 2022, the size of anti-biofilm wound dressings industry was estimated at USD 745.8 million. It is expected that the sector will expand at a compound annual growth rate (CAGR) of 8.25% and resulting in approximately USD 1,647.45 million by 2032.

Certain important anti-biofilm agents are used to stop the development of biofilms and clean the surface of wounds, including wound gel, polyhexamethylene biguanide, cadexomor iodine, poloxamer-based surfactant, and honey.

Market Growth:

Due to its shown capacity to hinder epithelialization, granulation tissue development, and typical inflammatory processes, as well as shield wound pathogens from medicines and antiseptics, biofilm is a hindrance to wound healing. To combat wound infections that are mostly found in biofilm form, a project was started to create a hybrid anti-biofilm/antimicrobial technology that could be included in a wound dressing.

This study was created to assess the anti-biofilm properties of eight commercially available wound care products using recognized in vitro biofilm assays due to the frequency and pathogenicity of biofilms in wounds. Dressings with various ionic silver delivery methods, such as nanocrystalline, gelling fibers, polyurethane (PU) foam, and polymer matrix, were among the goods studied. Companies in the worldwide anti-biofilm wound dressing industry are concentrating on creating a cutting-edge anti-biofilm matrix, coming up with efficient treatments for chronic wounds to increase patient survival, and creating therapies for wound healing.

Anti-Biofilm Wound Dressing Industry Report Scope:

Report Coverage Details
Market Size in 2022 USD 745.8 Million
Projected Forecast Value in 2032 USD 1,647.45 Million
Growth Rate from 2023 to 2032 CAGR of 8.25%
Largest Market North America
Base Year 2022
Forecast Period 2023 to 2032
Regions Covered North America, Europe, Asia-Pacific, Latin America and Middle East & Africa

Regional Analysis:

North America's largest industry share belongs to the United States. A few variables that contribute to industry growth in this region include an increase in chronic wounds, an increase in traffic accidents, and the presence of sizable ambulatory surgery clinics. Increased healthcare spending, a competent workforce, and a well-developed infrastructure all support industry expansion in this area.

In Europe, wounds are a rising problem that requires a range of resources to cure. In the UK, a number of surveys were undertaken. The aging population and rising frequency of long-term chronic illnesses are likely to drive growth in the anti-biofilm wound dressing industry in the United Kingdom.

In the world industry for anti-biofilm wound dressings, Asia Pacific is regarded as having the quickest rate of growth. During the anticipated period, it is thought that expanding healthcare infrastructure would accelerate industry expansion. The industry for anti-biofilm wound dressings is expanding due to the country's and China's expanding number of wound care facilities. The Asia Pacific industry for anti-biofilm wound dressings is expected to increase significantly as China focuses on establishing advanced wound care management facilities in the nation's main cities.

Market Dynamics:


Increased in the chronic diseases

Inflammation of the wound is induced and maintained by biofilms, which also raises the risk of infection and slows healing. To combat local and systemic infection and to rebalance the wound environment, proper biofilm management is necessary. The use of mechanical methods is the most efficient way to eliminate biofilms, and wound dressing is a crucial part of this approach.

An important therapy approach and active area of investigation is the targeted destruction of biofilms in chronic wounds. An in vitro model of chronic wound biofilms was created in the current study to evaluate the effectiveness of antimicrobial therapies used in the wound environment.

Following cancer surgery, the majority of surgical wounds are deep and substantial, resulting in exudates that require daily management. As a consequence, it is anticipated that the rising prevalence of chronic diseases would increase product demand, driving up the industry for anti-biofilm wound dressings globally. Iodine and silver-based anti-biofilm wound dressings assist in managing wounds and preventing infection.


Increasing treatment cost

Due to rising pricing for wound care supplies, the overall cost of wound therapy has increased. The cost of wound care products has been affected by changes in the industry pricing of synthetic anti-biofilm agents. Furthermore, public adoption of anti-biofilm wound dressing is constrained by the hazards involved with wound care procedures.

Infection issues might result from using the wrong dressing or applying it incorrectly. In some instances, improper wound dressing or wound care strategies directly contribute to wounds not healing. The industry's expansion is hampered by such wound care treatment concerns.


A novel antibacterial wound dressing has been evaluated in terms of its clinical safety and efficacy

In order to control exudate, infection, and biofilm, the next-generation antimicrobial wound dressing (NGAD; AQUACEL® Ag+ ExtraTM dressing) was evaluated for both safety and efficacy in this study. Clinicians were asked to assess the NGAD in problematic wounds that were thought to be hampered by suspected biofilm or infection within their regular protocol of treatment for up to 4 weeks, or as long as deemed clinically appropriate. Using standardized assessment forms, baseline data and post-evaluation dressing safety and efficacy data were collected. This information comprised wound exudate amounts and wound bed characteristics, including possible biofilm, wound progression, skin health, and dressing usage.

Mode of Mechanism Insights:

With a sizeable industry share, the chemical mode of the mechanism segment is expected to continue expanding during the projection period. Both chronic and acute wounds are thought to benefit from chemical-based anti-bio wound dressings. Iodine silver, iodine, EDTA, and other chemicals make up the chemical section. It is anticipated that the biological category would grow significantly throughout the projection period. Dispersion B, lactoferrin, bacteriophage, and other biological components are further divided into separate segments.

Wound Type Insights:

The anti-biofilm wound dressing industry is divided into acute and chronic wounds based on the type of wound. Due to the rise in trauma cases globally, surgical and traumatic wounds had a sizable part of the industry in 2023. Open, deep lesions called ulcers are regularly found on the bottoms of feet and are frequently brought on by chronic illnesses like diabetes. Such chronic wounds take a long time to heal, and some may never fully recover.

End-User Insights:

During the projection period, it is expected that the home care industry would have a considerable growth. The populace was obliged to use home care wound dressing services in 2020 due to the emergence of the coronavirus. An important driver of the hospital segment's growth in the worldwide anti-biofilm wound dressing industry is the increase in hospital admissions for surgical procedures. The segment's expansion has been spurred by the accessibility of cutting-edge wound treatment techniques and long-term care choices for wound healing.

Recent Developments:

  • In February 2023, the launch of Vista Wound Care Services in Waukegan, Illinois, was announced by the American company Vista Health Systems. The mission of the Vista Wound Care Services Center is to offer cutting-edge care for both acute and chronic wounds that can fend off infection and lower the chance of tissue loss and amputations. Services from Vista will be available in Waukegan and the nearby communities.
  • In January 2023, the University of Newcastle researchers partnered with the maker of therapeutic products Whiteley Corporation, situated in Hunter, in order to provide cutting-edge remedies for chronic wounds. The results of this alliance might lead to medical advancement in Australia and other countries. This partnership intends to develop a number of therapies, including anti-biofilm therapy, wound mapping, and wound debridement.
  • In January 2023, In order to do research on chronic wounds, Ampcontrol formed a cooperation with Whiteley Corporation. The federal government's Cooperative Research Centers Program has awarded Ampcontrol, an electrical engineering firm, a grant worth $5.6 million over three years.
  • In January 2023, PhaseOne Health announced the extension of its commercial program for the wound care industry by forging a collaborative collaboration with NovaBay, an innovative wound dressing producer in the United States. The team is working together to develop a unique therapy for wound care.

Major Key Players:

  • Conva-Tec
  • Smith & Nephew Plc
  • Coloplast
  • 3M
  • Urgo Medical
  • Imbed Biosciences
  • Lohmann & Rauscher

Market Segmentation:

By Mode of Mechanism

  • Physical
  • Chemical
  • Biological

By Wound Type

  • Acute wounds
  • Chronic wounds

By End-Users

  • Hospitals
  • Specialty clinics
  • Home healthcare

Buy this Research Report@

You can place an order or ask any questions, please feel free to contact at | +1 9197 992 333